Skip to main content
. 2021 Jul 3;38(2):282–289. doi: 10.1007/s12288-021-01466-1

Fig. 2.

Fig. 2

a Overall survival in relapsed/refractory chronic lymphocytic leukaemia patients with ibrutinib monotherapy, b progression free survival in relapsed/refractory chronic lymphocytic leukaemia with ibrutinib monotherapy. SHG: secondary hypogammaglobulinemia